Scientists test 'Universal' immune cells to battle tough leukemia
NCT ID NCT07026942
Summary
This study is testing a new treatment for acute myeloid leukemia (AML) that has returned or not responded to other therapies. It uses specially engineered immune cells from a healthy donor, designed to find and attack the cancer. The first part finds the safest dose, and the second part tests how well it works. Patients are young (ages 1-39) and will receive chemotherapy followed by the new cell infusion.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.